American Airlines (AA), which almost a week ago announced the expansion of its summer routes, has announced that, effective 1 January 2026, its employee health plan will restrict coverage of GLP-1 (glucagon-like peptide-1) medications for weight management. Only crew members with a diagnosis of Type 2 diabetes will retain coverage for drugs such as Ozempic and Mounjaro; those using Wegovy and Saxenda will be completely excluded.
The decision has provoked a strong reaction from the Association of Professional Flight Attendants (APFA), the union representing the carrier’s flight crews, says that this change “reduces the value of your healthcare coverage and strips treatment options Members rely on for prevention and quality of life“.
Which are the ten most punctual US airlines for January 2025?
American Airlines Flight Attendant’s Policy Change Details
American Airlines’ announcement which can be seen in Association of Professional Flight Attendants(APFA) says that the health-plan will:
” only cover GLP-1 medications for individuals with type 2 diabetes. Within that group, coverage will be limited only to Ozempic® and Mounjaro®. This means that Wegovy® and Saxenda® will be completely excluded from coverage, even if medically necessary or prescribed by your physician.”
After having a notification of the changes, the APFA said that “this change raises serious concerns for our Members”. It also highlighted that there were other alternatives such as:
- Introduction of copay limits to reduce members’ personal financial burden.
- Establishment of prior-authorization procedures to confirm medical necessity before treatment approval.
- Deployment of step-therapy frameworks that prioritize lower-cost, clinically effective alternatives before advancing to higher-priced medications.
What do the critics have to say?
President Donald Trump has said that he intends to bring down the costs of “Ozempic”, something he referred to “the fat loss drug” to $150 from $1,300. According to Reuters, “Ozempic has a list price of about $1,000 for a month’s supply but is sold directly by Novo to cash-pay customers for $499 per month“.
One Mile at a Time suggested that American Airlines’ financial position may have influenced its decision to reduce certain healthcare benefits for employees. The report also discussed the growing use of Ozempic for weight management, noting that the medication has had a significant impact on many patients while its high retail price can make it difficult for people to afford without insurance coverage.
The report pointed out that Ozempic can cost around $1,000 per month at retail prices, putting the annual expense beyond the reach of many consumers. It also noted that questions remain about the medication’s long-term health effects, despite its widespread use and reported benefits for weight management.
One Mile at a Time also linked American Airlines’ healthcare changes to the carrier’s broader cost pressures. The airline has relatively high labor expenses and has faced weaker profitability than major competitors such as Delta Air Lines and United Airlines, potentially increasing pressure to identify areas where costs can be reduced.
From that perspective, changes to employee healthcare coverage could form part of a broader effort by American Airlines to control expenses and improve its financial performance.
Top 5: Ways in which US airports are adapting to cater to travelers with accessibility requirements
Bottom line
American Airlines’ decision to curb GLP-1 medication coverage for non-diabetic weight management among its crew signifies a striking intersection of the following dynamics:
- Employee health benefits
- Cost-control imperatives
- Union-employer dynamics
It is unsurprising that the exclusion of weight-loss uses of drugs such as Wegovy and Saxenda has brought forth strong union backlash, raising questions about the future of health-benefit design in this busiest airlines of the US.
_E175_N413YX_KMIA_NASEDIT_(47110424032).jpg){kind=link}